232 related articles for article (PubMed ID: 30314604)
1. Molecular Imaging of Addictive Behavior in Idiopathic Parkinson's Disease.
Ghadery C; Valli M; Mihaescu A; Strafella R; Navalpotro I; Kim J; Strafella AP
Int Rev Neurobiol; 2018; 141():365-404. PubMed ID: 30314604
[TBL] [Abstract][Full Text] [Related]
2. [¹¹C]-(+)-PHNO PET imaging of dopamine D(2/3) receptors in Parkinson's disease with impulse control disorders.
Payer DE; Guttman M; Kish SJ; Tong J; Strafella A; Zack M; Adams JR; Rusjan P; Houle S; Furukawa Y; Wilson AA; Boileau I
Mov Disord; 2015 Feb; 30(2):160-6. PubMed ID: 25641350
[TBL] [Abstract][Full Text] [Related]
3. Hyperdopaminergic behavioral spectrum in Parkinson's disease: A review.
Béreau M; Fleury V; Bouthour W; Castrioto A; Lhommée E; Krack P
Rev Neurol (Paris); 2018 Nov; 174(9):653-663. PubMed ID: 30224159
[TBL] [Abstract][Full Text] [Related]
4. Molecular imaging and neural networks in impulse control disorders in Parkinson's disease.
Aracil-Bolaños I; Strafella AP
Parkinsonism Relat Disord; 2016 Jan; 22 Suppl 1(Suppl 1):S101-5. PubMed ID: 26298389
[TBL] [Abstract][Full Text] [Related]
5. Unmasking neurobiological commonalities between addictive disorders and impulse control disorders in Parkinson's disease.
Ramdave S; Dawson A; Carter A; Dissanayaka NNW
Brain Imaging Behav; 2020 Dec; 14(6):2785-2798. PubMed ID: 30707344
[TBL] [Abstract][Full Text] [Related]
6. Molecular Imaging of Opioid System in Idiopathic Parkinson's Disease.
Thobois S; Brefel-Courbon C; Le Bars D; Sgambato-Faure V
Int Rev Neurobiol; 2018; 141():275-303. PubMed ID: 30314599
[TBL] [Abstract][Full Text] [Related]
7. Psychostimulant effect of dopaminergic treatment and addictions in Parkinson's disease.
Delpont B; Lhommée E; Klinger H; Schmitt E; Bichon A; Fraix V; Castrioto A; Quesada JL; Pélissier P; Kistner A; Carnicella S; Lüscher C; Broussolle E; Pollak P; Thobois S; Krack P
Mov Disord; 2017 Nov; 32(11):1566-1573. PubMed ID: 28737225
[TBL] [Abstract][Full Text] [Related]
8. [Hypothesis: Parkinson's disease, reward deficiency syndrome and addictive effects of levodopa].
Linazaroso G; van Blercom N; Lasa A
Neurologia; 2004 Apr; 19(3):117-27. PubMed ID: 15088161
[TBL] [Abstract][Full Text] [Related]
9. Imaging impulse control disorders in Parkinson's disease and their relationship to addiction.
Ray NJ; Strafella AP
J Neural Transm (Vienna); 2013 Apr; 120(4):659-64. PubMed ID: 23232664
[TBL] [Abstract][Full Text] [Related]
10. Molecular Imaging of the Dopaminergic System in Idiopathic Parkinson's Disease.
de Natale ER; Niccolini F; Wilson H; Politis M
Int Rev Neurobiol; 2018; 141():131-172. PubMed ID: 30314595
[TBL] [Abstract][Full Text] [Related]
11. Dopaminergic function and intertemporal choice.
Joutsa J; Voon V; Johansson J; Niemelä S; Bergman J; Kaasinen V
Transl Psychiatry; 2015 Jan; 5(1):e491. PubMed ID: 25562841
[TBL] [Abstract][Full Text] [Related]
12. Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management.
O'Sullivan SS; Evans AH; Lees AJ
CNS Drugs; 2009; 23(2):157-70. PubMed ID: 19173374
[TBL] [Abstract][Full Text] [Related]
13. [Not Available].
Corvol JC
Bull Acad Natl Med; 2014 Oct; 198(7):1297-307; discussion 1307-8. PubMed ID: 27120903
[TBL] [Abstract][Full Text] [Related]
14. [Predictors and modifiers of impulse control disorders in Parkinson`s disease].
Sapronova MR; Shnayder NA
Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(11):145-156. PubMed ID: 28635753
[TBL] [Abstract][Full Text] [Related]
15. Positron emission tomography in Parkinson's disease: insights into impulsivity.
Stark AJ; Claassen DO
Int Rev Psychiatry; 2017 Dec; 29(6):618-627. PubMed ID: 29206483
[TBL] [Abstract][Full Text] [Related]
16. Behavioral addictions in early-onset Parkinson disease are associated with DRD3 variants.
Castro-Martínez XH; García-Ruiz PJ; Martínez-García C; Martínez-Castrillo JC; Vela L; Mata M; Martínez-Torres I; Feliz-Feliz C; Palau F; Hoenicka J
Parkinsonism Relat Disord; 2018 Apr; 49():100-103. PubMed ID: 29361389
[TBL] [Abstract][Full Text] [Related]
17. Intrinsic brain connectivity predicts impulse control disorders in patients with Parkinson's disease.
Tessitore A; De Micco R; Giordano A; di Nardo F; Caiazzo G; Siciliano M; De Stefano M; Russo A; Esposito F; Tedeschi G
Mov Disord; 2017 Dec; 32(12):1710-1719. PubMed ID: 28949049
[TBL] [Abstract][Full Text] [Related]
18. Extrastriatal dopaminergic changes in Parkinson's disease patients with impulse control disorders.
Lee JY; Seo SH; Kim YK; Yoo HB; Kim YE; Song IC; Lee JS; Jeon BS
J Neurol Neurosurg Psychiatry; 2014 Jan; 85(1):23-30. PubMed ID: 24023269
[TBL] [Abstract][Full Text] [Related]
19. Dyskinesias and impulse control disorders in Parkinson's disease: From pathogenesis to potential therapeutic approaches.
Jiménez-Urbieta H; Gago B; de la Riva P; Delgado-Alvarado M; Marin C; Rodriguez-Oroz MC
Neurosci Biobehav Rev; 2015 Sep; 56():294-314. PubMed ID: 26216865
[TBL] [Abstract][Full Text] [Related]
20. Functional brain imaging of cognitive dysfunction in Parkinson's disease.
Hirano S; Shinotoh H; Eidelberg D
J Neurol Neurosurg Psychiatry; 2012 Oct; 83(10):963-9. PubMed ID: 22807560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
